Clinical Trial Update: This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating canakinumab or pembrolizumab as monotherapy or in combination for early-stage non-small cell lung cancer was terminated, wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Canakinumab (canakinumab)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2023-07-03